Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), characterized by the gut mucosal ulceration. Growing evidence indicates that dysregulation of immune response to the commensal microbiota involves the pathogenesis of IBD. Previous studies have demonstrated the favorable probiotic effects of fermented rice extracts through triple fermentation with Saccharomyces cerevisiae and Weissella cibaria (FRe). Thus, the therapeutic potential of FRe for UC was examined. Dextran sodium sulfate UC mice model was orally administered distilled water as a control, sulfasalazine, or FRe at 300, 200, and 100 mg/kg, once a day for a week. The UC control exhibited body weight loss, bloody stools, and colonic shortening. However, the FRe, especially at 300 mg/kg, led to a reduction in weight loss, disease activity index scores, and colon weight, and an increase in colorectal length. The histopathological analyses revealed mild changes involved in the colonic crypt and mucosal damages in the FRe groups, along with inhibited inflammation. Indeed, the FRe reduced neutrophil infiltration and production of proinflammatory cytokines (i.e., tumor necrosis factor‐α, interleukin‐6/‐8). This was accompanied by the down‐regulation of nuclear factor‐kappa B. The gene expression responsible for the intestinal barrier integrity (i.e., Zonna occludens‐1/‐2, Claudin‐1, Occludin, Mucin‐1/‐2) was up‐regulated in the FRe groups. In addition, the FRe reduced lipid peroxidation and enhanced antioxidant activity. Interestingly, the microbiota dysbiosis was attenuated in the FRe groups, and the number of beneficial bacteria, Lactobacilli and Bifidobacteria, was increased. It suggests that the FRe potently ameliorate UC as a functional food.

Highlights

  • Inflammatory bowel diseases (IBDs) include two main types of ulcerative colitis (UC) and Crohn's disease, which is characterized by chronic and recurrent inflammation with mucosal ulceration in the gut. (Hanauer, 2006)

  • The major medications are focused on the control of inflammation and immunomodulation, and they include sulfasalazaine, prednisone, azathioprine, and antibodies against tumor necrosis factor (TNF)-α and integrin (Hanauer, 2006)

  • UC is triggered predominantly by the epithelial invasion of the intestinal microbiota due to the loss of the epithelial layer integrity (Matsuoka & Kanai, 2015). This leads to the overproduction of proinflammatory cytokines (i.e., TNF-α, interleukin [IL]-1β and IL-6) and colonic ulceration and damage

Read more

Summary

| INTRODUCTION

Inflammatory bowel diseases (IBDs) include two main types of ulcerative colitis (UC) and Crohn's disease, which is characterized by chronic and recurrent inflammation with mucosal ulceration in the gut. (Hanauer, 2006). UC is triggered predominantly by the epithelial invasion of the intestinal microbiota due to the loss of the epithelial layer integrity (Matsuoka & Kanai, 2015). This leads to the overproduction of proinflammatory cytokines (i.e., TNF-α, interleukin [IL]-1β and IL-6) and colonic ulceration and damage. The potential efficacy of probiotics or prebiotics for the treatment of UC has engendered interest (Laurell & Sjoberg, 2017) They are considered as safe food constituents involved in the regulation of the microbita balance and intestinal function (Vanderhoof & Young, 1998), and selective growth-stimulation of the beneficial microbiota (Komiyama et al, 2011). The therapeutic potential of FRe for UC was assessed in comparison with a treatment with sulfasalazine that down-regulates nuclear factor-kappa B (NF-κB) pathway (Gan, Chen, & Ouyang, 2005)

| MATERIALS AND METHODS
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call